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Abstract
Previous studies on parathyroid hormone (PTH)(1^14) revealed that residues (1^9) played a dominant role in stimulating
PTH-1 receptor-mediated increases in cAMP formation. In the present study, we examined the effects of installing a metal-
binding motif in the (10^14) region of rat PTH(1^14) on the peptide’s agonist activity. We found that substitution of histidine
for the native asparagine at position 10 of PTH(1^14) provided a peptide that was approx. 8-fold more potent as an agonist
in the presence of divalent zinc salts than it was in the absence of the metal. This enhancement in potency was dependent on
the native histidine at position 14, the concentration of Zn(II) utilized, and did not occur with other divalent metal ions. The
zinc-activated [His10]-PTH(1^14) peptide was blocked by a classical PTH-1 receptor antagonist, PTHrP(7^36), and did not
activate the PTH-2 receptor. The zinc-mediated enhancing effect did not require the large N-terminal extracellular domain of
the PTH-1 receptor. Although we were able to demonstrate that [His10]-PTH(1^14) binds Zn(II) using 1H-NMR, our
spectroscopic studies (circular dichroism and nuclear magnetic resonance) were not consistent with the notion that zinc
enhanced the activity of [His10]-PTH(1^14) simply by inducing a helical structure in the 10^14 region. Rather, the data
suggest that the enhancement in cAMP potency arises from the formation of a ternary complex between [His10]-PTH(1^14), a
zinc atom, and the extracellular loop/transmembrane domain region of the PTH-1 receptor. ß 2001 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Parathyroid hormone (PTH) is the primary biolog-
ical agent responsible for calcium ion homeostasis in
humans [1]. PTH exerts its e¡ects by binding to the
PTH/PTHrP receptor, or PTH-1 receptor, a family B
G protein-coupled receptor [2]. The activated PTH-1
receptor mediates increases in the production of
cAMP, as well as other second messenger signaling
molecules [3]. This same receptor also mediates the
developmental actions of PTHrP [1,3]. The peptide
PTH(1^34) produces an equivalent biological re-
sponse to the native PTH(1^84) in vitro (EC50 values
approx. 1 nM for cAMP activation) [4], and clinical
studies have now indicated that PTH(1^34) has
powerful anabolic e¡ects on bone density in osteo-
porotic postmenopausal women [5^7]. We recently
reported that high micromolar concentrations of
the shorter analogue PTH(1^14) are capable of acti-
vating cAMP formation in cells expressing high lev-
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els of the PTH-1 receptor (approx. 1 000 000 recep-
tors/cell) [8]. More recently, we have shown that the
potency of the PTH(1^14) peptide can be improved
considerably through the incorporation of particular
amino acid changes, such that the analogue
[Ala3;10;12,Arg11,Trp14]-PTH(1^14)NH2 is approx.
220-fold more potent than native PTH(1^14)NH2
(EC50 values approx. 0.6 WM and 133 WM, respec-
tively) [9]. At present, the molecular mechanism(s) by
which these substitutions enhance the potency of the
PTH(1^14) sca¡old is unknown.
The observation that prompted the present study
took the form of a paradox: the (10^14) region of
PTH(1^14) was found to be highly tolerant towards
substitution by a variety of residues, yet deletion of
even one residue from the C-terminus of PTH(1^14)
led to severe reductions in bioactivity [8,9]. These
observations raised the possibility that the (10^14)
region did not make critical contacts with the recep-
tor, but rather contributed to peptide activity indi-
rectly (e.g. by stabilizing the secondary structure in
the (1^9) region of the peptide). We hypothesized,
therefore, that the (10^14) region might be tolerant
of new structural motifs that would provide advan-
tages in terms of analyzing the interactions between
PTH(1^14) and the PTH-1 receptor. Herein we de-
scribe our e¡orts to install a metal-binding domain
into the (10^14) region of PTH(1^14). A metal-based
approach to the analysis of peptide ligand/receptor
interactions has potential advantages over more con-
ventional covalent modi¢cation strategies [10^13], in
that the structure of the metal/ligand chelate can be
‘tuned’ through the use of metals with di¡erent bind-
ing geometries, as well as by varying the metal-ligat-
ing residues in either the ligand or the receptor
[14,15]. The results of our study reveal that a met-
al-binding domain can be installed into the (10^14)
region of PTH(1^14) and that this new domain con-
fers a metal-dependent enhancement in cAMP-stim-
ulating potency to the modi¢ed peptide.
2. Materials and methods
2.1. Peptide synthesis
All peptides utilized in this study contained a car-
boxy-terminal amide and a free amino group at
the N-terminus. Analogues of rat PTH(1^14)NH2
(native PTH(1^14)) and shorter length PTH peptides
were synthesized on a multiple peptide synthesizer
(Advanced Chemtech model 396 MBS) using Fmoc
(N-(9-£uorenyl)methoxycarbonyl) main chain pro-
tecting group chemistry, HBTU/HOBt/DIEA
(O-benzotriazol-1-yl-N,N,NP,NP-tetramethyluronium
hexa£uorophosphate/1-hydroxybenzotriazole/N,N-d-
iisopropylethylamine) (1:1:2 molar ratio) for cou-
pling reactions, and TFA (tri£uoroacetic acid)-
mediated cleavage/side chain deprotection (MGH
Biopolymer Synthesis Facility, Boston, MA). Pep-
tides were desalted by adsorption on a C18-
containing cartridge (Sep-Pak). The peptides
[Nle8;21,Tyr34]-rat-PTH(1^34)NH2 (PTH(1^34)) and
[Leu11,D-Trp12,Trp23,Tyr36]-human-PTHrP(7^36)N-
H2 ({[Leu11,D-Trp12]-PTHrP(7^36)) were prepared
on an Applied Biosystems model 431A peptide syn-
thesizer using the same coupling chemistry and TFA-
mediated cleavage/deprotection; these peptides were
puri¢ed by HPLC (high performance liquid chroma-
tography). All peptides were reconstituted in 10 mM
acetic acid and stored at 380‡C. The purity, identity,
and stock concentration of each compound was se-
cured by analytical HPLC, mass spectrometry and
amino acid analysis, respectively.
2.2. Cell culture
COS-7 and LLC-PK1-derived cells were cultured
at 37‡C in T-75 £asks (75 mm2) in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) supplemented with
fetal bovine serum (10%), penicillin G (20 units/ml),
streptomycin sulfate (20 Wg/ml) and amphotericin B
(0.05 Wg/ml) in a humidi¢ed atmosphere containing
5% CO2. Stock solutions of EGTA/trypsin and anti-
biotics were from Gibco; fetal bovine serum was
from Hyclone Laboratories (Logan, UT). The
HKRK-B7 cell line was derived by stable transfec-
tion of LLC-PK1 porcine kidney cells with a
pCDNA-1-based plasmid containing the human
PTH-1 receptor cDNA and expresses approx.
950 000 receptors/cell [16]. Cells were subcultured in
24-well plates and, when con£uent, were treated with
fresh medium before assay [17].
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2.3. PTH receptor expression in COS-7 cells
The pCDNA1-based plasmids encoding the intact
rat PTH-1 receptor or the truncated rat PTH-1 re-
ceptor (P1R-delNt) were used for studies in COS-7
cells [8]. This mutant receptor is deleted for residues
26^181 and thus has Leu25 joined directly to Glu182
located at the C-terminal end of the N-terminal
extracellular domain (residues 1^23 are the predicted
signal sequence and are thus removed during pro-
cessing of the receptor to the cell surface). Transient
transfections of COS-7 cells were performed using
DEAE-dextran and 200 ng of cesium chloride-puri-
¢ed plasmid DNA per well of a 24-well plate, as
described previously [17].
2.4. cAMP stimulation
Stimulation of cells with peptide analogues was
performed in 24-well plates. Cells were rinsed with
0.5 ml of binding bu¡er (50 mM Tris-HCl, 100 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 5% heat-inactivated
horse serum, 0.5% fetal bovine serum, adjusted to
pH 7.7 with HCl) and treated with 100 Wl of
cAMP assay bu¡er (Dulbecco’s modi¢ed Eagle’s me-
dium containing 2 mM IBMX (3-isobutyl-1-methyl-
xanthine), 1 mg/ml bovine serum albumin, 35 mM
HEPES-NaOH, pH 7.4), 100 Wl of cAMP assay bu¡-
er containing varying amounts of metal salts, and
100 Wl of binding bu¡er containing varying amounts
of peptide analogue (¢nal volume = 300 Wl). The me-
dium was removed after incubation for 1 h at room
temperature, and the cells were frozen (380‡C), lysed
with 0.5 ml 50 mM HCl, and refrozen (380‡C). The
cAMP content of the diluted lysate was determined
by radioimmunoassay. For inhibition studies, the an-
tagonist peptide, [Leu11,D-Trp12]-PTHrP(7^36), was
added to the rinsed cells in 100 Wl of cAMP assay
bu¡er immediately prior to the addition of 100 Wl of
cAMP assay bu¡er containing ZnCl2 and 100 Wl of
cAMP assay bu¡er containing the agonist peptide
(¢nal volume = 300 Wl) ; the cells were then incubated
for 60 min at room temperature and processed as
described above.
2.5. Circular dichroism spectroscopy
CD (circular dichroism) spectra were recorded us-
ing a Jasco CD spectrometer. The samples contained
peptides at concentrations of 20 WM in either phos-
phate bu¡er (50 mM, pH 7.4) or phosphate bu¡er
containing TFE (tri£uoroethanol) (20% v/v). The
samples were analyzed at 20‡C; ten scans (255^
185 nm) were averaged for each spectrum. Only
small variations in the spectra were observed over a
range of temperatures (4^24‡C) and peptide con-
centrations (5^40 WM). The ellipticity values are re-
ported as the mean residue molar ellipticity in
degWcm2/dmol. Estimates of ‘% helicity’ were cal-
culated according to the formula: %hx =
((3]2223[3]coil)/([3]max3[3]coil))U100, where [3]222
was the observed ellipticity at 222 nM, [3]max was
taken to be 340 000 degWcm2/dmol, and [3]coil was
estimated as 0 degWcm2/dmol [10].
2.6. NMR spectroscopy
One-dimensional 1H-NMR (nuclear magnetic res-
onance) spectra were recorded using a Varian 600
MHz spectrometer at 20‡C. A solution of [His10]-
PTH(1^14)NH2 (2 mM) was ¢rst prepared in
50 mM deuterated HEPES/2H2O (pH 7.0, not cor-
rected for deuterium). To a portion of the sample, 10
equivalents of zinc tri£uoromethanesulfonate (Al-
drich) were added, the pH (6.8) was readjusted to
7.0 with NaO2H and the turbidity was eliminated
by centrifugation. The two solutions were then di-
rectly analyzed in parallel runs on the spectrometer;
the chemical shifts of the aromatic regions of the
resulting spectra are reported in Table 2.
2.7. Data calculation
Calculations were performed using Microsoft Ex-
cel. Curves were ¢t to the data using nonlinear re-
gression analysis [9]. The statistical signi¢cance be-
tween two data sets was determined using a one-
tailed Student’s t-test assuming unequal variances
for the two sets. Statistical signi¢cance (test vs. con-
trol) is indicated throughout the ¢gures as follows:
*P6 0.01; **P6 0.001; ***P6 0.0001.
3. Results
Our study began with a ‘histidine scan’ through
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the (10^13) region of PTH(1^14); ¢ve peptide ana-
logues were synthesized using standard solid phase
techniques, the sequences of which are summarized
in Table 1. The cAMP responses induced by the
[HisX]-PTH(1^14) analogues (and the native
PTH(1^14) and PTH(1^34) controls) in LLC-PK1
Table 1
Primary structures of the C-terminal regions of the PTH(1^14) analogues utilized in this study
PTH(1^14) analogue Residue at indicated position
9 10 11 12 13 14
Nativea His Asn Leu Gly Lys His
His scan analogues
His10 His His Leu Gly Lys His
His11 His Asn His Gly Lys His
His12 His Asn Leu His Lys His
His13 His Asn Leu Gly His His
His10, His13 His His Leu Gly His His
More potent analogues
Ala3, His10 His His Leu Gly Lys His
His10, Arg11 His His Arg Gly Lys His
His10, Ala12 His His Leu Ala Lys His
His10, Arg11, Ala12 His His Arg Ala Lys His
Position 14 analogues
His10, Ala14 His His Leu Gly Lys Ala
His10, Cys14 His His Leu Gly Lys Cys
His10, Met14 His His Leu Gly Lys Met
Model K-helix
EAAAK His Glu Ala Ala Ala Lys
aThe complete sequence of native PTH(1^14) is H-Ala-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-NH2.
Fig. 1. Histidine scan analysis of the (10^14) region of PTH(1^14). The peptides [Nle8;21,Tyr34]-PTH(1^34)NH2 (PTH), rat PTH-
(1^14)NH2 (Native) and several histidine-substituted PTH(1^14) analogues (cf. Table 1) were tested at the indicated concentrations for
the ability to stimulate cAMP formation in LLC-PK1 cells that stably express the PTH-1 receptor (HKRK-B7 cells). The peptides
were assayed in the absence (control) and presence of either 300 WM NiCl2 or 300 WM ZnCl2. Data (mean+S.E.M.) are from dupli-
cate wells of a single representative experiment. The statistical signi¢cance of the di¡erence from the control response is indicated as
*P6 0.01.
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cells stably transfected with the human PTH-1 recep-
tor (HKRK-B7 cells) in the presence of bu¡er alone
or bu¡er containing NiCl2 or ZnCl2 (300 WM each)
are shown in Fig. 1. The responses observed in the
absence of metal ion revealed that substitution of
histidine at position 12 or 13 caused little or no e¡ect
on the agonist activity of the (1^14) sca¡old; in con-
trast, histidine substitution at position 10 or 11 re-
sulted in peptides that were each less active than
native PTH(1^14). The signaling responses of these
modi¢ed PTH(1^14) analogues, as well as that of
native PTH(1^14), was not signi¢cantly altered by
the addition of NiCl2 to the assay medium. However,
both [His10]-PTH(1^14) and [His11]-PTH(1^14)
showed statistically signi¢cant 4-fold increases in
cAMP generation in the presence of ZnCl2 (Fig. 1).
Although [His10]-, [His11]- and [His10;13]-PTH(1^14)
were all substantially less potent than was native
PTH(1^14) for stimulating cAMP in the absence of
metal ion, only [His10]-PTH(1^14) was as potent as
native PTH(1^14) in the presence of Zn(II). None of
the other peptides, including PTH(1^34), was af-
fected by the presence of ZnCl2. For the remainder
of the study we focused on [His10]-PTH(1^14), which
had greater intrinsic agonist activity than did [His11]-
PTH(1^14).
Other divalent metals that vary in Lewis acidity
from hard (Mg) to soft (Cd) [15] were examined
for their ability to enhance the agonist activity of
[His10]-PTH(1^14) (Fig. 2A). Among the metals
tested, only Zn(II) enhanced the response elicited
by the peptide analogue. Variation of the metal
counterion did not a¡ect the zinc-mediated enhance-
ment, as identical results were obtained with ZnCl2,
Zn(ONO2)2 and Zn(OAc)2 (data not shown). The
ZnCl2-mediated enhancement of [His10]-PTH(1^14)
agonist activity was dependent on the concentration
of metal ion utilized, and the enhancement reached a
maximum between 100 and 300 WM ZnCl2 (Fig. 2B).
Higher concentrations of ZnCl2 (s 300 WM) resulted
in markedly diminished total cAMP responses with
each peptide tested (data not shown), an e¡ect likely
due to nonspeci¢c cytotoxicity. A comparison of the
e¡ects of di¡erent concentrations of ZnCl2 on vary-
ing concentrations of [His10]-PTH(1^14) revealed
that enhancement was not observed below a thresh-
old concentration of 30 WM ZnCl2 (Fig. 2B). At con-
centrations higher than this threshold, enhancement
increased proportionally, such that the fold increase
(metal/no metal) was 1.9-fold at a metal/peptide ratio
of 1:1, and rose to 7.5-fold at a metal/peptide ratio
of 30:1 (Fig. 2B). Although a full concentration-re-
sponse analysis was not performed, an 8^9-fold im-
provement in the potency of [His10]-PTH(1^14) oc-
Fig. 2. In£uence of metal identity and stoichiometry on the agonist activity of [His10]-PTH(1^14). (A) The peptide [His10]-PTH(1^14)
was tested at a 100 WM concentration for the ability to stimulate cAMP formation in HKRK-B7 cells in the absence (None) and pres-
ence of 100 WM concentrations of the indicated metal(II) chloride salts. Data (mean+S.E.M.) are taken from duplicate wells of a sin-
gle representative experiment and are shown as the fold increase over the response induced by [His10]-PTH(1^14) in the absence of
metal salt. (B) Three di¡erent concentrations of [His10]-PTH(1^14) were tested for the ability to stimulate cAMP accumulation in
HKRK-B7 cells in the presence of varying concentrations of ZnCl2. Data (mean+S.E.M.) are from duplicate wells of a single repre-
sentative experiment. The statistical signi¢cance of the di¡erence from the corresponding cAMP response in the absence of metal is in-
dicated as follows: *P6 0.01; **P6 0.001.
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curred in the presence of 300 WM zinc, such that the
cAMP response observed with 11 WM of [His10]-
PTH(1^14) (+zinc) was the same as that seen with
100 WM [His10]-PTH(1^14) (no zinc). This apparent
8-fold improvement in the potency of [His10]-PTH-
(1^14) was consistent with the e¡ect seen on the EC50
of [His10,Ala12]-PTH(1^14) (Fig. 5C).
We demonstrated previously that the agonist re-
sponse induced by PTH(1^14) can be inhibited by
the competitive antagonist [Leu11,D-Trp12]-
PTHrP(7^36), even when the antagonist peptide is
present at a 10-fold molar de¢ciency relative to the
PTH(1^14) agonist [8]. As a means to assess whether
or not the ZnCl2 was substantially altering the site at
which the [His10]-PTH(1^14) engaged the receptor,
we examined the ability of [Leu11,D-Trp12]-
PTHrP(7^36) to block the cAMP response induced
by [His10]-PTH(1^14) in the presence and absence of
ZnCl2. In the absence of ZnCl2, a 10 WM concentra-
tion of [Leu11,D-Trp12]-PTHrP(7^36) signi¢cantly re-
duced the response to both 100 WM PTH(1^14) and
100 WM [His10]-PTH(1^14) by the same proportion,
81% (Fig. 3A). In the presence of ZnCl2, the antag-
onist reduced the cAMP response to both peptides,
again by the same proportion, 45% (Fig. 3B). Thus,
while the e¡ectiveness of the PTHrP(7^36) antago-
nist ^ which itself contains four histidines at posi-
tions 9, 25, 26, and 32 ^ was partially diminished
by ZnCl2, it antagonized both the unenhanced (na-
tive) and zinc-enhanced (His10) PTH(1^14) analogues
to the same extent.
The capacity of zinc to mediate enhancement of
[His10]-PTH(1^14) activity in other cell types and
with other PTH-1 receptors was assessed in transi-
ently transfected COS-7 cells (Fig. 4). In COS-7 cells
expressing the human PTH-1 receptor, a 100 WM
concentration of ZnCl2 mediated a 2-fold enhance-
ment in the cAMP response elicited by 100 WM
[His10]-PTH(1^14) (Fig. 4A). This enhancement was
statistically signi¢cant and compared favorably to
that observed in HKRK-B7 cells (cf. Fig. 2B). The
small e¡ect that ZnCl2 exerted on the basal signaling
rate in HKRK-B7 cells (Fig. 1) was not observed in
COS-7 cells (Fig. 4A). As was found previously for
other PTH(1^14) analogues [8], [His10]-PTH(1^14)
was inactive with the human PTH-2 receptor ex-
Fig. 3. E¡ects of a competitive antagonist on the responses elicited by PTH(1^14) analogues in the presence and absence of ZnCl2.
(A,B) The ability of a 10 WM concentration of [Leu11,D-Trp12,Trp23,Tyr36]-PTHrP(7^36)NH2 (PTHrP(7^36)) to alter the cAMP re-
sponse elicited by binding bu¡er alone (None), 100 WM rat PTH(1^14)NH2 (Native) and 100 WM [His10]-PTH(1^14)NH2 (His10) in
HKRK-B7 cells in either the absence (A) or presence (B) of 100 WM ZnCl2 is shown. Data (mean+S.E.M.) are from duplicate wells
of a single representative experiment, and are normalized to the response induced by 100 WM native PTH(1^14) (no zinc added). The
statistical signi¢cance of the di¡erence from the corresponding cAMP response in the absence of PTHrP(7^36) antagonist is indicated
as follows: *P6 0.01.
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pressed in COS-7 cells, either in the presence or ab-
sence of ZnCl2 (Fig. 4A). A dose-dependent zinc-
mediated enhancement of [His10]-PTH(1^14) signal-
ing activity was observed in COS-7 cells expressing
the intact rat PTH-1 receptor, as well as in cells
transfected with a truncated variant of the rat
PTH-1 receptor that lacks most of the N-terminal
extracellular domain (rdelNt; Fig. 4B).
Recently, we identi¢ed several amino acid substi-
tutions in the PTH(1^14) backbone that additively
improve peptide potency [8,9]. To investigate
whether or not the activity-enhancing e¡ects of these
substitutions could be combined with the Zn(II)-
mediated enhancement of activity described above,
we synthesized and functionally analyzed three ana-
logues of [His10]-PTH(1^14) containing the substitu-
tions of Ser3CAla, Leu11CArg or Gly12CAla, as
well as a [His10]-PTH(1^14) analogue containing
both the Leu11CArg and Gly12CAla substitutions.
In the absence of ZnCl2 (Fig. 5A), the activity pro-
¢les of these modi¢ed [His10]-PTH(1^14) peptides
closely paralleled those seen previously for the anal-
ogous PTH(1^14) peptides containing asparagine at
position 10, although the potencies of the His-10-
containing analogues were predictably lower than
those observed previously for the corresponding
Asn-10-containing analogues [8,9]. Among the single
substitutions, Leu11CArg resulted in the greatest
improvement in activity, and potency was improved
further by combining this with Gly12CAla, such
that [His10,Arg11,Ala12]-PTH(1^14) was approx. 50-
fold more potent than [His10]-PTH(1^14). In the
presence of ZnCl2 (1:1 metal:peptide ratio) the two
[His10]-PTH(1^14) analogues that contained the
Arg11 substitution failed to respond to ZnCl2 (Fig.
5B). This negative e¡ect of the position 11 substitu-
tion on ZnCl2 responsiveness paralleled that seen for
the histidine-13 substitution, as [His10;13]-PTH(1^14)
also failed to respond to ZnCl2 (Fig. 1). In contrast,
both [Ala3,His10]-PTH(1^14) and [His10,Ala12]-
PTH(1^14) exhibited signi¢cant (s 2-fold) increases
in agonist activity in response to ZnCl2 (Fig. 5B). A
Fig. 4. The e¡ects of [His10]-PTH(1^14) on di¡erent PTH-1 receptors expressed in COS-7 cells in the presence and absence of ZnCl2.
(A) COS-7 cells transiently transfected with the intact human PTH-1 receptor (hP1Rc) or human PTH-2 receptor (hP2Rc) were tested
for the ability to mediate cAMP accumulation in response to binding bu¡er alone (no peptide) or [His10]-PTH(1^14)NH2 (His10) in
the presence and absence (control) of a 100 WM concentration of ZnCl2. (B) COS-7 cells transiently transfected with either the intact
rat PTH-1 receptor (rP1Rc-WT) or a truncated PTH-1 receptor (rP1R-delNt) lacking most (residues 26^181) of the amino-terminal
domain were tested for the ability to mediate cAMP accumulation in response to 100 WM [His10]-PTH(1^14)NH2 in the presence of
varying concentrations of ZnCl2. Data (mean+S.E.M.) are from duplicate wells of a single representative experiment. The statistical
signi¢cance of the di¡erence from the corresponding cAMP response in the absence of ZnCl2 is indicated as follows: *P6 0.01. Under
these transfection conditions, the expression level of rP1R-delNt was found to be 55% that of rP1Rc-WT [8] and that of hP2Rc was
9% that of hP1Rc [17].
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dose-response analysis of [His10,Ala12]-PTH(1^14)
performed in the absence and presence of ZnCl2
(100 WM) revealed that the modi¢ed analogue was
equipotent to native PTH(1^14) in the absence of
zinc, but was 8-fold more potent than native
PTH(1^14) in the presence of ZnCl2 (Fig. 5C).
The enhancement of [His10]-PTH(1^14) activity by
zinc was clearly dependent on the histidine modi¢ca-
tion at position 10, in that peptides that contained
Asn (native, cf. Fig. 1) or Glu (data not shown) at
position 10 were not activated by Zn(II). However,
the importance of the native histidines at positions 9
and 14 (Table 1) was uncertain. The high degree of
mutational intolerance of position 9 [8,9] precluded
us from determining the role of this site in mediating
the zinc response. Since position 14 is more tolerant
of modi¢cation [9], we synthesized three peptides
to evaluate the role of the histidine at this site in
mediating the zinc e¡ect: [His10,Ala14]-PTH(1^14),
[His10,Cys14]-PTH(1^14) and [His10,Met14]-PTH-
(1^14). Each of these peptides stimulated cAMP for-
mation with HKRK-B7 cells, but none responded
Fig. 5. E¡ects of select amino acid substitutions on the activity of [His10]-PTH(1^14) in the presence and absence of ZnCl2. (A) The
peptides rat PTH(1^14)NH2 (Native), [His10]-PTH(1^14)NH2 (H10) and several modi¢ed [His10]-PTH(1^14) analogues (substitutions
indicated in the ¢gure key) were tested at varying concentrations for the ability to stimulate cAMP formation in HKRK-B7 cells.
(B) The PTH(1^14) analogues shown in A were each tested at a 100 WM concentration for the ability to stimulate cAMP formation
in HKRK-B7 cells in the absence and presence of 100 WM ZnCl2. Shown is the fold increase over the response induced by the peptide
in the absence of ZnCl2. (C) The peptides rat PTH(1^14)NH2 (Native) and [His10,Ala12]-PTH(1^14)NH2 (H10,A12) were tested at
varying concentrations for their ability to stimulate cAMP production in HKRK-B7 cells in the absence (¢lled symbols) and presence
(open symbols) of 100 WM ZnCl2. Data (mean+S.E.M.) are from duplicate wells of single representative experiments. For B and C,
the statistical signi¢cance of the di¡erence from the corresponding cAMP response in the absence of ZnCl2 is indicated as follows:
*P6 0.01; **P6 0.001; ***P6 0.0001.
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signi¢cantly to ZnCl2 (Fig. 6). These results indicate
that the imidazole side chain at position 14 is a crit-
ical determinant of the Zn(II)-mediated enhancement
of [His10]-PTH(1^14) activity. In addition, the failure
of other sulfur-containing amino acids capable of
chelating Zn(II) to mediate a Zn(II) response when
introduced at position 14 in [His10]-PTH(1^14) sug-
gests that there are stringent geometrical and/or elec-
tronic constraints on the PTH(1^14)-Zn(II) interac-
tion.
Given that the two critical histidines in [His10]-
PTH(1^14) that mediate zinc responsiveness (His10
and His14) are in an (i, i+4) relationship, it seemed
plausible that Zn(II) enhanced the potency of this
peptide by stabilizing an K-helix in the (10^14) region
[18,19], which might in turn stabilize helix formation
in the (1^9) region, which is known to be critical for
receptor activation [9,20]. The importance of helicity
to the biological activity of the N-terminal domain of
PTH(1^34) has now been widely discussed [21^24].
We explored the validity of this helix induction hy-
pothesis by performing two parallel and independent
series of experiments. In the one, we examined the
potential for bimolecular complex formation between
Zn(II) and [His10]-PTH(1^14), and consequent helix
induction, using several spectroscopic methods (elec-
trospray mass spectrometry, CD, and 1H-NMR)
[18,19,25]; in the other, we synthesized a PTH-
(1^14) analogue that contained a heterologous model
K-helical sequence.
Under a variety of conditions (pH and metal load-
ing), we were unable to detect metal/peptide complex
formation utilizing electrospray mass spectrometry
(data not shown). Complexation of Zn(II) to
[His10]-PTH(1^14) was detected, however, by 1H-
NMR spectroscopy. Comparison of the one-dimen-
sional 600 MHz 1H-NMR spectra of [His10]-PTH-
(1^14) with the spectra obtained in the same bu¡er
containing 10 equivalents of zinc tri£ate revealed
that the addition of zinc produced changes (peak
position and shape) in both the backbone and side
chain resonances (Table 2). The most notable di¡er-
ences occurred in the aromatic regions of the spectra,
where the 2-H and 4-H protons of the three histi-
dines appeared as ¢ve separate resonances in zinc-
free solvent and as two broadened resonances in
the Zn(II)-containing solvent (Table 2). This de-
shielding of the aromatic resonances by zinc tri£ate
was not due to non-speci¢c binding of the metal to
Fig. 6. The zinc responsiveness of [His10]-PTH(1^14) analogues
with di¡erent amino acids at position 14. A series of
[His10,X14]-PTH(1^14)NH2 analogues (the residue at position 14
is indicated on the abscissa) were each tested at a 100 WM con-
centration for the ability to stimulate cAMP formation in
HKRK-B7 cells in the absence and presence of 100 WM ZnCl2.
Data (mean+S.E.M.) are from duplicate wells of a single repre-
sentative experiment and are normalized to the cAMP response
elicited by the control peptide rat PTH(1^14)NH2 (no zinc
added) in the same experiment (not shown). The statistical sig-
ni¢cance of the di¡erence from the corresponding cAMP re-
sponse in the absence of ZnCl2 is indicated as follows:
***P6 0.0001.
Table 2
Summary of 1H-NMR chemical shift dataa
Assignment No zinc 10 equiv. Zn(II) Av. change
2H-imidazole N 7.76, 7.75, 7.72 N 7.84, broad 30.097
4H-imidazole N 6.94, 6.89b N 6.96, broad 30.053
aChemical shift data are listed in ppm, referenced to the 2HOH resonance. The spectra of [His10]-PTH(1^14) were acquired in 50 mM
HEPES/2H2O (pH 7.0) in the presence and absence of 10 equivalents of zinc(II) tri£ate. See Section 2 for a full description of the ex-
periment.
bThis peak was of 2U intensity.
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the peptide backbone, as the zinc salts did not alter
the 1H-NMR spectra of [His10]-PTH(1^14) recorded
at lower pH where the histidines are protonated and
unable to coordinate zinc (data not shown). The CD
spectra of [His10]-PTH(1^14), recorded in both phos-
phate bu¡er (pH 7.4) and phosphate bu¡er contain-
ing 20% tri£uoroethanol, were identical to those re-
corded for native PTH(1^14) (cf. Fig. 7A,B, and data
not shown), and no changes in the spectra of either
peptide were observed upon the addition of Zn(II)
salts (data not shown).
The model helical analogue, [Glu10,Ala11;12;13,
Lys14]-PTH(1^14), is predicted to contain a stable
helix in the (10^14) region due to the presence of
the C-terminal lysine, which stabilizes the helix di-
pole, a Glu-Lys ion pair in an (i, i+4) arrangement,
and consecutive alanines as the intervening residues
[26^28]. Analysis of [Glu10,Ala11;12;13,Lys14]-PTH-
(1^14) by CD spectroscopy showed that this peptide
was indeed partially helical in pH 7.4 phosphate bu¡-
er, whereas native PTH(1^14), as well as the more
potent analogue [Ala3;10;12,Arg11]-PTH(1^14), exhib-
ited only marginal helical content in this purely aque-
ous solvent (Fig. 7A). The relative intensities of the
Fig. 7. Examination of a PTH(1^14) analogue containing a C-terminal K-helix-inducing sequence. (A,B) Shown are the CD spectra of
native PTH(1^14)NH2, [Ala3;10;12,Arg11]-PTH(1^14)NH2 and [Glu10,Ala11ÿ13,Lys14]-PTH(1^14)NH2 ; the spectra were obtained at room
temperature in either pH 7.4 phosphate bu¡er ((A) or 20% tri£uoroethanol/phosphate bu¡er ((B), as described in Section 2. (C) The
abilities of varying concentrations of native PTH(1^14)NH2, [Glu10,Ala11ÿ13,Lys14]-PTH(1^14)NH2, and [Ala3;10;12,Arg11]-PTH-
(1^14)NH2 to promote cAMP accumulation in HKRK-B7 cells are shown. (D) The abilities of rat PTH(1^14)NH2 (Native),
[Glu10,Ala11ÿ13,Lys14]-PTH(1^14)NH2 (EAAAK), and singly substituted PTH(1^14) analogues (substitution indicated on abscissa) to
stimulate cAMP production in HKRK-B7 cells at a single 100 WM concentration are shown. Data in C and D (mean+S.E.M.) are
from duplicate wells of a single representative experiment.
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[3]222 and [3]209 bands in the spectrum of
[Glu10,Ala11;12;13,Lys14]-PTH(1^14) were consistent
with the formation of a short 310-helix [29] (Table
3). In bu¡er containing 20% tri£uoroethanol, helical
content increased for all three PTH(1^14) analogues;
however, [Glu10,Ala11;12;13,Lys14]-PTH(1^14) was still
25^30% more helical than was native PTH(1^14) or
[Ala3;10;12,Arg11]-PTH(1^14) (Fig. 7B, Table 3). The
estimated helical content of 89% observed for the
model peptide in 20% TFE indicates that the K-helix
extended to the (1^9) region. Although
[Glu10,Ala11;12;13,Lys14]-PTH(1^14) induced a signi¢-
Fig. 8. Possible mechanisms by which Zn(II) enhances [His10]-PTH(1^14) activity. Two di¡erent working models are illustrated for the
interaction of [His10]-PTH(1^14)NH2 with ZnCl2. Model A: the Zn(II) binds to [His10]-PTH(1^14) and induces (or stabilizes) a more
favorable peptide conformation for stimulation of the PTH-1 receptor. Model B: the Zn(II) binds to both the PTH-1 receptor (site
unknown) and [His10]-PTH(1^14), thereby enhancing the e⁄ciency of receptor stimulation.
Table 3
Summary of CD spectroscopy data
Peptide Bu¡era Observedb [3]U1033 Helixc
[3]192 [3]209 [3]222 M222/209M M192/222M %hx
Native phos 0.6 34.2 30.7 0.17 0.85 3
Quad phos 5.5 34.6 0.3 ^ ^ 0
EAAAK phos 7.5 313.8 37.5 0.54 1.00 26
Native phos/TFE 23.3 318.9 315.8 0.84 1.47 55
Quad phos/TFE 28.5 321.6 318.2 0.84 1.56 64
EAAAK phos/TFE 55.6 330.0 325.3 0.84 2.20 89
aSpectra were recorded at room temperature in either 50 mM phosphate bu¡er (pH 7.4) or 20% tri£uoroethanol/phosphate bu¡er.
bObserved mean residue ellipticity (in units of 1033 degWcm2/dmol) at the indicated wavelengths (192, 209, and 222 nM) is shown; cf.
Fig. 7C,D for the complete curves.
cThe absolute values for the quotients of the indicated ellipticities are shown; for an ideal helix [41], M222/209M= 1.09 and M192/222M
= 2.63. The estimated ‘% helix content’ (%hx) was calculated as described in Section 2.
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cant stimulation of the receptor at a concentration of
100 WM (18% native PTH(1^14); 8.6-fold over basal,
P = 0.002), it was weak (Fig. 7C). In order to exam-
ine whether or not the dramatic decrease in the po-
tency of the model pentasubstituted peptide was due
to a speci¢c substitution, we evaluated the e¡ects of
each substitution individually (Fig. 7D): three re-
sulted in enhancement of activity at 100 WM
(Glu10, 139% native; Ala12, 236% native; and
Ala13, 113% native) and two resulted in a decrease
in activity at 100 WM (Ala11, 60% native; and Lys14,
35% native). Thus, while the model helical peptide
was certainly more potent than PTH(1^9), which
does not display any appreciable biological activity
at 100 WM [8], it was clearly not as potent as native
PTH(1^14) or Zn(II)-activated [His10]-PTH(1^14),
despite being considerably more helical. These data
lead to the conclusion that the residues in the (10^14)
region of PTH(1^14) are contacting the receptor di-
rectly [30], rather than simply inducing helix forma-
tion in the (1^9) region. The combined results of the
spectroscopy experiments and model peptide experi-
ments thus suggest that [His10]-PTH(1^14) can coor-
dinate Zn(II) under the pH conditions utilized in the
cAMP assay, but that this coordination does not
induce a stable helical structure in the absence of
the receptor.
4. Discussion
The objectives of the present study were to deter-
mine if a metal-binding motif could be introduced
into the (10^14) region of PTH(1^14), and to ascer-
tain whether or not such a modi¢cation would allow
for metal-mediated modulation of PTH(1^14) ago-
nist activity. The relatively simple structure of
PTH(1^14), as opposed to the more complex
PTH(1^34), provides a peptide backbone that is gen-
erally well suited for such structure-activity relation-
ship analyses [9,31]. A series of new histidine-con-
taining PTH(1^14) analogues was thus generated,
and our bioactivity data obtained for these analogues
(Figs. 1^4) showed the following: (i) [His10]-PTH-
(1^14) and [His11]-PTH(1^14) responded to ZnCl2 ;
(ii) this e¡ect was speci¢c to Zn(II), as opposed to
other divalent metal ions, but was not speci¢c to the
metal counterion; (iii) the e¡ect was speci¢c for the
type 1 PTH receptor, but not to the host cell used for
receptor expression or the species derivation of the
receptor; (iv) the zinc e¡ect did not require the major
portion of the N-terminal extracellular domain of the
receptor; and (v) the Zn-activated [His10]-PTH(1^14)
analogue could be antagonized by a conventional
PTH-1 receptor competitive antagonist. Our investi-
gation of the peptide determinants of the zinc e¡ect
(Figs. 1, 5 and 6) revealed that: (i) the e¡ect was
compatible with the activity-enhancing substitutions
of Ser3CAla and Gly12CAla, but was not compat-
ible with the insertion of certain polar residues within
the putative zinc-binding domain (Arg11 or His13),
and (ii) the e¡ect was dependent on the presence of
both the His10 modi¢cation and the native histidine
at position 14. Taken together, the data indicate that
Zn(II) salts mediate a highly speci¢c enhancement of
the agonist activity of [His10]-PTH(1^14) for the
PTH-1 receptor.
In studies with the glucagon receptor, another
family B G protein-coupled receptor, it was demon-
strated that the a⁄nity for agonists and antagonists
can be modulated by Mg(II) and Ca(II) [32,33], but
these e¡ects involved allosteric changes in the recep-
tor. Any model that does not consider the direct
participation of the ligand in metal ion binding
clearly cannot explain our results with [His10]-
PTH(1^14) and the PTH-1 receptor. Accordingly,
we derived two ¢rst-order models for the Zn(II)-in-
duced enhancement of the activity of the [His10]-
PTH(1^14) peptide that include the peptide in an
active role (Fig. 8). The ¢rst model (model A) pro-
poses that Zn(II) does not contact the receptor di-
rectly, but simply coordinates between the His10 and
His14 side chains of the peptide. This complexation
could enhance the potency of the peptide through
several mechanisms, including: (i) stabilization of a
favorable conformation in the (1^9) region, the (10^
14) region, or both; and (ii) simple improvement of
the molecular recognition properties of His10 itself,
an e¡ect that could occur, for example, by a zinc-
mediated deprotonation of an imidazole nitrogen
and the attendant conversion of that nitrogen from
an H-bond donor to an H-bond acceptor (rendering
the side chain more like that of Asn found in native
PTH(1^14) or Glu/Gln found in activity enhanced
PTH(1^14) analogues [9]). The second model (model
B) postulates something quite di¡erent: that Zn(II)
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mediates the formation of a ternary complex between
the peptide (via His10 and His14), the metal ion, and
the juxtamembrane region of the PTH-1 receptor,
and that formation of this complex results in more
e¡ective receptor stimulation. The enhancement in
stimulation due to ternary complex formation could
also occur through several mechanisms, including:
(i) simple improvement of the binding a⁄nity of
the peptide, thereby enabling more e¡ective/frequent
interaction of the critical (1^9) region with the juxta-
membrane region of the receptor; (ii) stabilization of
a bioactive conformation of the peptide; and (iii) the
induction of a change in receptor conformation that
is favorable for G protein coupling. It is important
to note, however, that our data with the competitive
antagonist suggest that such a ternary complex, if
formed, does not result in the use of a dramatically
di¡erent receptor site than that used by native
PTH(1^14). Both models A and B are consistent
with the fact that insertion of a metal-coordinating
residue, such as Arg or His, within the (11^13) region
can interrupt the Zn(II) e¡ect, presumably through
disruption of the critical His10-Zn-His14 chelate.
To help discriminate between the two suggested
models, we analyzed the ability of Zn(II) salts to
bind directly to [His10]-PTH(1^14) in aqueous solu-
tion in the absence of receptor. By 1H-NMR spec-
troscopic analysis, we determined that Zn(II) can
coordinate to [His10]-PTH(1^14). A number of stud-
ies on other small peptides have demonstrated that
metal coordination between i and i+4 residues can
stabilize an K-helical conformation [18,19], and re-
cent studies have suggested that the helicity in the
(1^9) region of PTH is important for receptor acti-
vation [21^24]. Thus, it seemed reasonable to pro-
pose that zinc(II) enhanced the activity of PTH-
(1^14) by inducing a helical structure in the (10^14)
region and thereby stabilizing helicity in the critical
(1^9) region. Neither our NMR data nor our data
obtained from CD spectroscopy, however, provided
support for the notion that Zn(II) coordination in-
duces a helical structure in the peptide. As an inde-
pendent test of the above hypothesis, we synthesized
a PTH(1^14) analogue containing a model K-helical
sequence [26^28] in the (10^14) region. As expected,
this peptide, [Glu10,Ala11;12;13,Lys14]-PTH(1^14), ex-
hibited markedly enhanced helicity relative to other
PTH(1^14) reference peptides; however, it was
barely active in our cAMP stimulation assay. The
collective ¢ndings clearly indicate that helicity per
se in the (10^14) region of PTH(1^14) is not su⁄cient
to improve the functional activity of the ligand and
suggest that Zn(II) most likely does not enhance the
potency of [His10]-PTH(1^14) via the induction of a
helical conformation. Nonetheless, our data certainly
do not exclude the other possibilities discussed above
for model A (Fig. 8).
In consideration of model B (Fig. 8), it is impor-
tant to note that we observed signi¢cant enhance-
ment in activity at a zinc/peptide ratio of 1:1. In
general, the a⁄nity of Zn(II) for peptides containing
only two histidines is quite weak (Kd approx. 0.1
mM), such that a 300-fold excess of zinc is typically
required to observe a maximal e¡ect [18]. Such weak
a⁄nity would be consistent with our inability to de-
tect direct ligation of Zn(II) to [His10]-PTH(1^14) by
electrospray mass spectroscopy. When it is further
considered that a threshold concentration of Zn(II)
was required to see the zinc-based e¡ect on peptide
activity (regardless of the metal/peptide ratio, cf. Fig.
2B), it becomes reasonable to postulate that the re-
ceptor provides a third point of metal ligation. The
threshold concentration that was required in our
studies (approx. 30 WM) is similar to the reported
a⁄nities with which ZnCl2 bound to several other
G protein-coupled receptors (Kd approx. 10^100
WM) [34,35]. We found that preincubation of the
PTH-1 receptor with ZnCl2, followed by washing
with bu¡er and subsequent addition of [His10]-
PTH(1^14), did not result in a zinc-dependent en-
hancement of the peptide’s activity (data not shown).
This result suggests that Zn(II) does not allosterically
induce a long-lived conformational change in the re-
ceptor.
Our experiments with PTH-1 receptor variants
suggest that any peptide/metal/receptor ternary com-
plex that forms utilizes a receptor site that is shared
by the human and rat receptor subtypes. Further-
more, our studies with the truncated rat PTH-1 re-
ceptor demonstrated that the major portion of the
large, extracellular N-terminal domain of the recep-
tor ^ which normally provides interactions with the
(15^34) domain of PTH [36,37] ^ is not a site of
metal chelation relevant to the [His10]-PTH(1^14)
analogue. Previous studies on the PTH-1 receptor
and the related glucagon receptor in cell membrane
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preparations suggested that the cytoplasmic surface
of the receptor can be a site of metal binding [32^34],
but such sites are unlikely to play a role in our
present investigations conducted in whole cells. In-
stead, it seems more plausible that residue(s) located
in the extracellular loops or the extracellular ends of
the transmembrane helices play a role in mediating
the e¡ects of Zn(II) on [His10]-PTH(1^14) activity.
These regions of the receptor have been shown to
contain determinants of ligand interaction by a num-
ber of mutational and photochemical crosslinking
studies [36,38^40]. The use of site-directed mutagen-
esis strategies might permit the mapping of the pu-
tative zinc-binding site(s) in the PTH-1 receptor that
are relevant to our present study. Such information,
together with our current data on short peptide li-
gands, could help to constrain and re¢ne the com-
puter-based models of the PTH/PTH receptor com-
plex that are now being developed [22,24].
In summary, we have demonstrated that a highly
speci¢c interaction between Zn(II) and [His10]-
PTH(1^14) results in enhanced stimulation of the
PTH-1 receptor by a novel mechanism. The data
presented herein may have positive implications for
enhancing a⁄nity/e⁄cacy of other peptidic and/or
even smaller molecule agonists for the PTH-1 recep-
tor. Our present e¡orts are focused on both expand-
ing the range of ligand and receptor substrates that
respond to Zn(II), and on identifying the receptor
residues that are involved in modulating these ef-
fects.
Acknowledgements
We acknowledge Dr. Andrew Tyler (Dept. of
Chemistry, Harvard University) for performing
mass spectrometry experiments. We thank Prof.
Gregory Verdine (Dept. of Chemistry, Harvard Uni-
versity) for providing equipment for CD spectrosco-
py. We thank Drs. Peggy Scherle, Neil Farrow, Rob-
ert Cherney, and Andrew Tebben for helpful
discussions and critical reviews of the manuscript.
This project was supported by the National Institutes
of Health grant DK11794.
References
[1] H. Kronenberg, A. Abou-Samra, F. Bringhurst, T. Gardella,
H. Ju«ppner, G. Segre, in: R. Thakker (Ed.), Genetics of
Endocrine and Metabolic Disorders, Chapman and Hall,
London, 1997, pp. 389^420.
[2] L.F. Kolakowski, Recept. Channels 2 (1994) 1^7.
[3] H. Ju«ppner, A.-B. Abou-Samra, M. Freeman, X.-F. Kong,
E. Schipani, J. Richards, L.F. Kolakowski Jr., J. Hock, J.T.
Potts Jr., H.M. Kronenberg, G.V. Segre, Science 254 (1991)
1024^1026.
[4] T.J. Gardella, D. Rubin, A.B. Abou-Samra, H.T. Keut-
mann, J.T. Potts Jr., H.M. Kronenberg, S.R. Nussbaum,
J. Biol. Chem. 265 (1990) 15854^15859.
[5] D.W. Dempster, F. Cosman, M. Parisien, V. Shen, R. Lind-
say, Endocr. Rev. 14 (1993) 690^709.
[6] H. Plotkin, C. Gundberg, M. Mitnick, A.F. Stewart, J. Clin.
Endocrinol. Metab. 83 (1998) 2786^2791.
[7] E. Roe, S. Sanchez, G. del Puerto, E. Pierini, P. Bacchetti,
C. Cann, C. Arnaud, J. Bone Miner. Res. 14 (Suppl 1)
(1999) S137.
[8] M.D. Luck, P.H. Carter, T.J. Gardella, Mol. Endocrinol. 13
(1999) 670^680.
[9] M. Shimizu, J.T. Potts, J. r, T.J. Gardella, J. Biol. Chem.
275 (2000) 21836^21843.
[10] D.Y. Jackson, D.S. King, J. Chmielewski, S. Singh, P.G.
Schultz, J. Am. Chem. Soc. 113 (1991) 9391^9392.
[11] M. Chorev, E. Roubini, R.L. McKee, S.W. Gibbons, M.E.
Goldman, M.P. Caul¢eld, M. Rosenblatt, Biochemistry 30
(1991) 5968^5974.
[12] H.E. Blackwell, R.H. Grubbs, Angew. Chem. Int. Ed. 37
(1998) 3281^3284.
[13] J.C. Phelan, N.J. Skelton, A.C. Braisted, R.S. McDowell,
J. Am. Chem. Soc. 119 (1997) 455^460.
[14] G.R. Dieckmann, D.K. McRorie, D.L. Tierney, L.M. Ut-
schig, C.P. Singer, T.V. O’Halloran, J.E. Penner-Hahn, W.F.
DeGrado, V.L. Pecoraro, J. Am. Chem. Soc. 119 (1997)
6195^6196.
[15] J.P. Glusker, Adv. Protein Chem. 42 (1991) 1^76.
[16] H. Takasu, J. Guo, F.R. Bringhurst, J. Bone Miner. Res. 14
(1999) 11^20.
[17] C. Bergwitz, S. Jusseaume, M. Luck, H. Ju«ppner, T. Gar-
della, J. Biol. Chem. 272 (1997) 28861^28868.
[18] M.R. Ghadiri, C. Choi, J. Am. Chem. Soc. 112 (1990) 1630^
1632.
[19] F. Ruan, Y. Chen, P.B. Hopkins, J. Am. Chem. Soc. 112
(1990) 9403^9404.
[20] M. Shimizu, P. Carter, T. Gardella, J. Biol. Chem. 275
(2000) 19456^19460.
[21] S.M. Condon, I. Morize, S. Darnbrough, C.J. Burns, B.E.
Miller, J. Uhl, K. Burke, N. Jariwala, K. Locke, P.H. Kro-
likowski, N.V. Kumar, R.F. Labaudiniere, J. Am. Chem.
Soc. 122 (2000) 3007^3014.
BBAMCR 14739 20-4-01
P.H. Carter, T.J. Gardella / Biochimica et Biophysica Acta 1538 (2001) 290^304 303
[22] L. Jin, S. Briggs, S. Chandrasekhar, N. Chirgadze, D. Claw-
son, R. Schevitz, D. Smiley, A. Tashjian, F. Zhang, J. Biol.
Chem. 275 (2000) 27238^27244.
[23] U. Marx, K. Adermann, P. Bayer, M. Meyer, W. For-
ssmann, P. Rosch, J. Biol. Chem. 273 (1998) 4308^4316.
[24] C. Ro«lz, M. Pellegrini, D.F. Mierke, Biochemistry 38 (1999)
6397^6405.
[25] U. Herr, W. Spahl, G. Trojandt, W. Steglich, F. Thaler, R.
van Eldik, Bioorg. Med. Chem. 7 (1999) 699^707.
[26] S. Marqusee, R.L. Baldwin, Proc. Natl. Acad. Sci. USA 84
(1987) 8898^8902.
[27] S. Marqusee, V.H. Robbins, R.L. Baldwin, Proc. Natl.
Acad. Sci. USA 86 (1989) 5286^5290.
[28] K.R. Shoemaker, P.S. Kim, E.J. York, J.M. Stewart, R.L.
Baldwin, Nature 326 (1987) 563^567.
[29] C. Toniolo, A. Polese, F. Formaggio, M. Crisma, J. Kam-
phuis, J. Am. Chem. Soc. 118 (1996) 2744^2745.
[30] A. Adams, A. Bisello, M. Chorev, M. Rosenblatt, L. Suva,
Mol. Endocrinol. 12 (1998) 1673^1683.
[31] P. Carter, M. Shimizu, M. Luck, T. Gardella, J. Biol. Chem.
274 (1999) 31955^31960.
[32] G.G. Chicci, M.P. Graziano, G. Koch, P. Hey, K. Sullivan,
P.P. Vicario, M.A. Cascieri, J. Biol. Chem. 272 (1997) 7765^
7769.
[33] M.A. Cascieri, G.E. Koch, E. Ber, S.J. Sadowski, D. Loui-
zides, S.E. de Laszlo, C. Hacker, W.K. Hagmann, M. Mac-
Coss, G.G. Chicchi, P.P. Vicario, J. Biol. Chem. 274 (1999)
8694^8697.
[34] S.P. Sheikh, J.-P. Vilardarga, T.J. Baranski, O. Lichtarge, T.
Iiri, E.C. Meng, R.A. Nissenson, H.R. Bourne, J. Biol.
Chem. 274 (1999) 17033^17041.
[35] C.E. Elling, K. Thirstup, B. Holst, T.W. Schwartz, Proc.
Natl. Acad. Sci. USA 96 (1999) 12322^12327.
[36] C. Bergwitz, T. Gardella, M. Flannery, J.T. Potts Jr., H.
Kronenberg, S. Goldring, H. Ju«ppner, J. Biol. Chem. 271
(1996) 26469^26472.
[37] M. Mannstadt, M. Luck, T. Gardella, H. Ju«ppner, J. Biol.
Chem. 273 (1998) 16890^16896.
[38] V. Behar, A. Bisello, B. Bitan, M. Rosenblatt, M. Chorev,
J. Biol. Chem. 275 (1999) 9^17.
[39] A. Bisello, A.E. Adams, D. Mierke, M. Pellegrini, M. Rose-
nblatt, L. Suva, M. Chorev, J. Biol. Chem. 273 (1998)
22498^22505.
[40] C. Lee, M. Luck, H. Ju«ppner, J.T. Potts Jr., H. Kronenberg,
T. Gardella, Mol. Endocrinol. 9 (1995) 1269^1278.
[41] J.-R. Barbier, W. Neugebauer, W. Morley, V. Ross, M.
Soska, J.F. Whit¢eld, G. Willick, J. Med. Chem. 40 (1997)
1373^1380.
BBAMCR 14739 20-4-01
P.H. Carter, T.J. Gardella / Biochimica et Biophysica Acta 1538 (2001) 290^304304
